NO. 84
CIMR Wednesday Lecture Series
Time:
Wednesday, Sep. 24 2025, 4:00 p.m.
Location:
Yifu Lecture Hall, North Basic Research Building
Host：
Xin Zhou (周欣)
Chinese Institutes for Medical Research, Beijing
Speaker：
Weidong Han (韩为东)
Professor
Department of Bio-Therapeutic
Chinese PLA General Hospital
TITLE：
Clinical exploration of innovative anti-tumor immunotherapy
ABSTRACT:
Introducing dual-target CART, epigenetically modified CART, and universal CART in the research of B-cell malignancies in the hematologic system; tumor GSL synthesis and immune escape from immunotherapy, as well as the development of universal CART based on similar principles applied in T-cell immune tolerance studies. Introducing epigenetic immune anti-tumor combination therapies.
SELECTED PAPERS
1. Nie J, Wang C, Zheng L, Liu Y, Wang C, Chang Y, Hu Y, Guo B, Pan Y, Yang Q, Hu X, Han W. Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma. Blood. 2024 Oct 31;144(18):1936-1950.
2. Yan X, Chen D, Wang Y, Guo Y, Tong C, Wei J, Zhang Y, Wu Z, Han W. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduct Target Ther. 2022 Apr 4;7(1):98.
3. Wu Z, Shi J, Lamao Q, Qiu Y, Yang J, Liu Y, Liang F, Sun X, Tang W, Chen C, Yang Q, Wang C, Li Z, Zhang H, Yang Z, Zhang Y, Yi Y, Zheng X, Sun Y, Ma K, Yu L, Yang H, Wang Z, Zheng W, Yang L, Zhang Z, Zhang Y, Wu Z, Wang Y, Wong CCL, Jin M, Yuan P, Han W, Wei W. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell. 2025 Aug 14:S0092-8674(25)00910-9.
10 Xitoutiao, Youanmen Wai, Fengtai District, Beijing 100069, China
010-86738999
cimr@cimrbj.ac.cn
中文
